文献
J-GLOBAL ID:201902266352114352
整理番号:19A1711251
2型糖尿病患者における腎臓病の進行と進行に対するダパグリフロジンの効果: DECLARE-TIMI58無作為化試験からの分析【JST・京大機械翻訳】
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
著者 (21件):
Mosenzon Ofri
(Diabetes Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel)
,
Wiviott Stephen D
(TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA)
,
Cahn Avivit
(Diabetes Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel)
,
Rozenberg Aliza
(Diabetes Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel)
,
Yanuv Ilan
(Diabetes Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel)
,
Goodrich Erica L
(TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA)
,
Murphy Sabina A
(TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA)
,
Heerspink Hiddo J L
(University Medical Center Groningen, University of Groningen, Groningen, Netherlands)
,
Zelniker Thomas A
(TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA)
,
Dwyer Jamie P
(Vanderbilt University Medical Center, Nashville, TN, USA)
,
Bhatt Deepak L
(TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA)
,
Leiter Lawrence A
(Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada)
,
McGuire Darren K
(University of Texas Southwestern Medical Center, Dallas, TX, USA)
,
Wilding John P H
(University of Liverpool, Liverpool, UK)
,
Kato Eri T
(Kyoto University Graduate School of Medicine, Kyoto, Japan)
,
Gause-Nilsson Ingrid A M
(AstraZeneca, Molndal, Sweden)
,
Fredriksson Martin
(AstraZeneca, Molndal, Sweden)
,
Johansson Peter A
(AstraZeneca, Molndal, Sweden)
,
Langkilde Anna Maria
(AstraZeneca, Molndal, Sweden)
,
Sabatine Marc S
(TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA)
,
Raz Itamar
(Diabetes Unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel)
資料名:
Lancet Diabetes & Endocrinology
(Lancet Diabetes & Endocrinology)
巻:
7
号:
8
ページ:
606-617
発行年:
2019年
JST資料番号:
W3110A
ISSN:
2213-8587
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)